# Circulating Tumor Cells in Glioblastoma

## TL;DR

This review explores how glioblastoma cells can enter the bloodstream as circulating tumor cells, offering new non-invasive ways to monitor and treat the disease.

## Contribution

The paper highlights the novel detection of glioblastoma CTCs and their potential for liquid biopsy in neuro-oncology.

## Key findings

- Glioblastoma CTCs challenge the traditional view of the disease as non-metastatic.
- CTCs can provide insights into tumor heterogeneity and treatment response.
- Specialized methods are needed to detect and analyze these rare CTCs.

## Abstract

Glioblastoma, the most aggressive primary brain tumor, has long been known to metastasize only in extremely rare cases, making systemic spread an exceptional finding. Nevertheless, recent advances have shown that glioblastoma cells can enter the bloodstream as circulating tumor cells (CTCs), challenging traditional assumptions about the disease’s strictly localized behavior. This review outlines current knowledge on glioblastoma CTC biology, detection methods, and clinical implications. Despite technical challenges—including their rarity and the lack of typical markers—glioblastoma CTCs provide a non-invasive way to monitor disease, guide treatment, and better understand tumor progression. Ongoing studies aim to improve CTC analysis sensitivity and integrate CTC insights with emerging therapies, ultimately advancing precision medicine for glioblastoma patients.

Glioblastoma multiforme (GBM) remains a devastating brain tumor with poor prognosis, traditionally viewed as non-metastatic. The recent detection of circulating tumor cells (CTCs) in glioblastoma challenges this long-held view and opens new opportunities for liquid biopsy in neuro-oncology. This review summarizes current understanding of glioblastoma CTCs, emphasizing their unique properties, detection technologies, and differences compared to CTCs in extracranial cancers. Key challenges include their rarity, the absence of epithelial markers, and the presence of the blood–brain barrier. Despite the need for specialized enrichment approaches, CTC analysis in glioblastoma can offer helpful information regarding tumor heterogeneity, treatment response, and minimal residual disease. We discuss emerging clinical studies leveraging CTCs for early relapse detection and therapy monitoring. Integrating CTC phenotyping with molecular and functional characterization may enhance future personalized treatment strategies in glioblastoma. Refined CTC methodologies combined with other liquid biopsy modalities may transform glioblastoma management, improving patient outcomes through less invasive, dynamic tumor surveillance.